TrioxBio's API, S-ethylisothiouronium diethylphosphate, MTR-104 (MTR- 105), is a nitric oxide synthase (NOS) inhibitor which blocks the production of nitric oxide, preventing the dilation of blood vessels and the other detrimental effects caused by excessive NOS activity. MTR-105, a fast-acting synthetic NOS inhibitor with rapid onset of action when administered parenterally, has been effective in alleviating hypotension experimentally and in several observational studies while reducing NO production. MTR-105 is registered and approved for clinical use in the Republic of Moldova where data have been collected from 434 patients exposed to the drug in pre- and postapproval clinical investigations.

Othera Pharmaceuticals originally developed OT-730 (now known as QLT 091568) as an oculoselective beta-blocker for reducing the elevated intraocular pressure associated with glaucoma. OT-730 was involved in phase II clinical trial in patients with ocular hypertension or open-angle glaucoma. However, these studies were discontinued. At December 30, 2009, QLT Inc. acquired OT-730.